Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University Health Center, McGill University, Montreal, Quebec, Canada.
Division of Clinical Epidemiology, McGill University Health Centre-Research Institute, Montreal, Quebec, Canada.
JAMA Psychiatry. 2019 Apr 1;76(4):426-434. doi: 10.1001/jamapsychiatry.2018.4500.
Cannabis is the most commonly used drug of abuse by adolescents in the world. While the impact of adolescent cannabis use on the development of psychosis has been investigated in depth, little is known about the impact of cannabis use on mood and suicidality in young adulthood.
To provide a summary estimate of the extent to which cannabis use during adolescence is associated with the risk of developing subsequent major depression, anxiety, and suicidal behavior.
Medline, Embase, CINAHL, PsycInfo, and Proquest Dissertations and Theses were searched from inception to January 2017.
Longitudinal and prospective studies, assessing cannabis use in adolescents younger than 18 years (at least 1 assessment point) and then ascertaining development of depression in young adulthood (age 18 to 32 years) were selected, and odds ratios (OR) adjusted for the presence of baseline depression and/or anxiety and/or suicidality were extracted.
Study quality was assessed using the Research Triangle Institute item bank on risk of bias and precision of observational studies. Two reviewers conducted all review stages independently. Selected data were pooled using random-effects meta-analysis.
The studies assessing cannabis use and depression at different points from adolescence to young adulthood and reporting the corresponding OR were included. In the studies selected, depression was diagnosed according to the third or fourth editions of Diagnostic and Statistical Manual of Mental Disorders or by using scales with predetermined cutoff points.
After screening 3142 articles, 269 articles were selected for full-text review, 35 were selected for further review, and 11 studies comprising 23 317 individuals were included in the quantitative analysis. The OR of developing depression for cannabis users in young adulthood compared with nonusers was 1.37 (95% CI, 1.16-1.62; I2 = 0%). The pooled OR for anxiety was not statistically significant: 1.18 (95% CI, 0.84-1.67; I2 = 42%). The pooled OR for suicidal ideation was 1.50 (95% CI, 1.11-2.03; I2 = 0%), and for suicidal attempt was 3.46 (95% CI, 1.53-7.84, I2 = 61.3%).
Although individual-level risk remains moderate to low and results from this study should be confirmed in future adequately powered prospective studies, the high prevalence of adolescents consuming cannabis generates a large number of young people who could develop depression and suicidality attributable to cannabis. This is an important public health problem and concern, which should be properly addressed by health care policy.
大麻是全世界青少年最常滥用的毒品。尽管青少年吸食大麻对精神病发展的影响已经被深入研究,但关于大麻使用对年轻人的情绪和自杀倾向的影响却知之甚少。
提供青少年吸食大麻与随后发生重度抑郁症、焦虑症和自杀行为风险之间关联程度的综合估计。
从创建到 2017 年 1 月,对 Medline、Embase、CINAHL、PsycInfo 和 ProQuest Dissertations and Theses 进行了检索。
选择了评估 18 岁以下青少年(至少有 1 个评估点)大麻使用情况,并随后确定年轻人(18-32 岁)抑郁发展情况的前瞻性和纵向研究,提取了针对基线抑郁和/或焦虑和/或自杀存在情况进行调整的比值比(OR)。
使用研究三角研究所(Research Triangle Institute)关于观察性研究偏倚风险和精度的项目库评估研究质量。两名评审员独立进行了所有评审阶段。使用随机效应荟萃分析汇总选定的数据。
纳入了评估青少年时期到成年早期不同时间点大麻使用情况和抑郁情况并报告相应 OR 的研究。在所选择的研究中,根据《精神障碍诊断与统计手册》第三或第四版或使用具有预定截断值的量表对抑郁进行诊断。
在筛选了 3142 篇文章后,有 269 篇文章进行了全文审查,有 35 篇文章进行了进一步审查,有 11 项研究(共 23317 人)被纳入定量分析。与非使用者相比,成年早期使用大麻者患抑郁症的 OR 为 1.37(95%CI,1.16-1.62;I2=0%)。焦虑的汇总 OR 没有统计学意义:1.18(95%CI,0.84-1.67;I2=42%)。自杀意念的汇总 OR 为 1.50(95%CI,1.11-2.03;I2=0%),自杀企图的 OR 为 3.46(95%CI,1.53-7.84,I2=61.3%)。
尽管个体风险仍然处于中低水平,且本研究结果需要在未来充分有力的前瞻性研究中得到证实,但青少年吸食大麻的高流行率导致了大量可能因大麻而发展为抑郁和自杀的年轻人。这是一个重要的公共卫生问题和关注点,应通过医疗保健政策妥善解决。